A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype-Reference-Cited by-同舟云学术

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

Published:2021-04-03 Issue:3 Volume:14 Page:954-963
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Baretti Marina¹,Karunasena Enusha¹,Zahurak Marianna²,Walker Rosalind¹,Zhao Yang³,Pisanic Thomas R.³,Wang Tza‐Huei³,Greten Tim F.⁴,Duffy Austin G.⁴,Gootjes Elske⁵,Meijer Gerrit⁵,Verheul Henk M.W.⁵,Ahuja Nita⁶,Herman James G.⁷,Azad Nilofer S.¹

Affiliation:

1. Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland USA

2. Department of Oncology, Biostatistics Johns Hopkins University School of Medicine Baltimore Maryland USA

3. Johns Hopkins Institute for NanoBioTechnology Baltimore Maryland USA

4. Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda Maryland USA

5. Amsterdam University Medical Center, location VUMC Amsterdam and Radboud UMC Nijmegen The Netherlands

6. Oncology and Pathology Smilow Cancer Hospital Yale University School of Medicine New Haven Connecticut USA

7. Department of Medicine UPMC Hillman Cancer Center University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12960

Reference52 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

3. Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis

4. DNA mismatch repair in cancer

5. The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan;Cell Cycle;2023-06-02

2. Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer;Advanced Science;2023-06

3. DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-05

4. DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1;Biomolecules;2022-03-08

5. Epigenetic therapy and DNA damage response;Epigenetics and DNA Damage;2022